NCT06711471 2024-12-02Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting31 enrolled